Addentax Group (NASDAQ:ATXG) Ltd. (NASDAQ: ATXG) is a specialty pharmaceutical company dedicated to the development and commercialization of advanced drug delivery systems designed to improve the absorption and therapeutic performance of peptide and small-molecule medications. The company’s proprietary platform technologies focus on non-invasive nasal and pulmonary administration routes, enabling rapid onset of action and enhanced bioavailability for treatments that traditionally require injection or oral dosing. By addressing the challenges of delivering drugs across mucosal barriers, Addentax aims to transform patient care in central nervous system and systemic indications.
Established through exclusive technology licensing from Weill Cornell Medicine, Addentax has built a diversified pipeline of delivery-enhanced drug candidates. Its flagship program applies the UniENTAX nasal formulation to facilitate transport of neuroactive compounds across the blood–brain barrier, with preclinical studies demonstrating promising pharmacokinetic and safety profiles. In parallel, the company is advancing additional applications that leverage its EntAX powder and liquid platforms for respiratory and systemic therapies, positioning each candidate for potential clinical development or strategic partnership.
Operating from its headquarters in the Cayman Islands, Addentax maintains research and development facilities in both China and the United States. The company has forged collaborations with contract research organizations, academic institutions and manufacturing partners to support formulation optimization, scale-up production and regulatory filings. By combining in-house expertise with external alliances, Addentax seeks to accelerate the progression of its delivery platforms toward first-in-human and later-stage clinical trials.
Guided by a management team with extensive backgrounds in pharmaceutical R&D, regulatory affairs and commercial strategy, Addentax is committed to advancing non-invasive drug administration technologies. The company’s strategic roadmap includes expanded clinical testing of lead candidates, out-licensing opportunities for its platform technologies and eventual commercialization partnerships. Through its innovative approach to drug delivery, Addentax aspires to set new standards for patient convenience and treatment efficacy across a broad range of therapeutic areas.
